ASSESSMENT OF RECOMBINANT ZOSTER VACCINE SECOND-DOSE COMPLETION IN THE UNITED STATES

B J Patterson[1]*, C-C Chen[2], C B McGuiness[2], L I Glasser[1], K Sun[2], P O Buck[1]

[1]GSK, Philadelphia, PA, USA, [2]IQVIA, Plymouth Meeting, PA, USA, *Presenting author: Brandon Patterson - brandon.j.patterson@gsk.com

OBJECTIVES

- Recombinant Zoster Vaccine (RZV) was licensed in the United States (US) in October 2017 for the prevention of herpes zoster in adults ≥50 years of age (YOA).[1]
- The vaccine is administered in a two-dose series with the 2nd dose recommended between 2-6 months after initial dose.[1]
- This study describes 2nd dose completion of RZV in the US within 6 and 12 months of initial dose.

METHODS

- Primary analysis was conducted on a cohort ≥50 YOA who received an initial RZV dose between October 2017 and September 2018 and had ≥1 year observation post initial dose.
- All eligible subjects regardless of the observable time were described in a sensitivity analysis.
- Monthly, 6-month cumulative and 12-month cumulative, 2nd dose completion with stratifications by age, sex, claim source and payer type was described.

RESULTS

Subject demographics



n: number of participants; **Y**: years.

RZV completion by 6 and 12 months



Y: years.

CONCLUSIONS

- **Assessment of RZV vaccination suggests high levels of completion across age, sex, payer type and claim sources by Month 6 post initial dose increasing further by Month 12. Sensitivity analyses were consistent with primary sample analyses.**
- **Significantly less completion was found in Medicaid patients and settings where vaccination claims are processed outside of the vaccine recipient's pharmacy benefit.**

Plain Language Summary

Completion of the RZV series was shown to be 70% at 6 months and 82% at 12 months after initial dose.

Funding: GlaxoSmithKline Biologicals SA (GSK study identifier: HO-18-19056)

Scan for more details

PDF